Medication company Viatris (NASDAQ: VTRS) reported Q1 CY2026 results beating Wall Street’s revenue expectations, with sales up 8.1% year on year to $3.52 billion. The company expects the full year’s revenue to be around $14.7 billion, close to analysts’ estimates. Its non-GAAP profit of $0.59 per share was 17.5% above analysts’ consensus estimates.
Is now the time to buy VTRS? Find out in our full research report (it’s free for active Edge members).
Viatris (VTRS) Q1 CY2026 Highlights:
- Revenue: $3.52 billion vs analyst estimates of $3.34 billion (8.1% year-on-year growth, 5.2% beat)
- Adjusted EPS: $0.59 vs analyst estimates of $0.50 (17.5% beat)
- Adjusted EBITDA: $1.05 billion vs analyst estimates of $928.3 million (29.8% margin, 13.1% beat)
- The company reconfirmed its revenue guidance for the full year of $14.7 billion at the midpoint
- Management reiterated its full-year Adjusted EPS guidance of $2.40 at the midpoint
- EBITDA guidance for the full year is $4.3 billion at the midpoint, in line with analyst expectations
- Operating Margin: -2.3%, up from -88.6% in the same quarter last year
- Market Capitalization: $20.25 billion
StockStory’s Take
Viatris delivered a positive first quarter, outperforming Wall Street’s expectations on both revenue and non-GAAP earnings per share. Management attributed this performance to strong commercial execution, particularly in Greater China, which saw accelerated growth driven by increased demand for cardiovascular products and successful e-commerce investments. CEO Scott Smith highlighted the company's execution and portfolio diversification, noting, “you’re seeing strong execution and our commercial investments are leading to accelerated growth.” The quarter also benefited from new product contributions in North America and operational improvements stemming from a strategic enterprise-wide review.
Looking ahead, Viatris’ guidance is underpinned by anticipated regulatory decisions and product launches, especially in the U.S. and Japan. Management emphasized the potential of the company’s late-stage pipeline, including the upcoming launches of XULANE LO and fast-acting meloxicam. Chief R&D Officer Philippe Martin stated, “We remain on track for the remaining 5 regulatory decisions in the second half of the year,” underscoring confidence in execution. The company is also prioritizing cost optimization and disciplined capital allocation, balancing shareholder returns with investments in business development to sustain long-term growth.
Key Insights from Management’s Remarks
Management credited the quarter’s results to strong geographic and product mix, targeted investments in China, and execution across a diversified portfolio while highlighting R&D progress and capital discipline.
- China commercial momentum: Accelerated growth in Greater China was a major driver, as favorable market fundamentals, an aging population, and targeted sales and e-commerce investments led to double-digit expansion and growing demand for cardiovascular products. Management noted that e-commerce sales in China more than doubled year-over-year.
- North America generics performance: Strong demand for estradiol and product launches in complex generics contributed to North American growth, with the company citing continued performance from Breyna and new complex generic introductions as key contributors.
- Product pipeline advancement: Viatris advanced its late-stage pipeline, receiving approval for EFFEXOR in Japan and progressing regulatory submissions for XULANE LO and fast-acting meloxicam in the U.S. Management also reported ongoing Phase III trials for selatogrel and cenerimod, which are expected to drive growth in coming years.
- Strategic cost optimization: The company continued implementing its enterprise-wide review, capturing cost savings and improving operational efficiency. These efforts contributed to better-than-expected operating expenses and EBITDA margin expansion, with a focus on reinvesting savings into growth opportunities.
- Leadership transition and stability: The transition to Interim CFO Paul Campbell was highlighted, with management emphasizing continuity in capital allocation strategy and ongoing commitment to balanced shareholder returns through dividends and share repurchases.
Drivers of Future Performance
Viatris’ outlook is anchored by new product launches, pipeline progression, and continued operational discipline, while management is closely monitoring policy and competitive risks.
- Upcoming regulatory milestones: Management is focused on securing regulatory approvals for XULANE LO and fast-acting meloxicam in the U.S., as well as additional product decisions in Japan and Europe. Successful launches and label updates are expected to support revenue acceleration and long-term growth.
- China and portfolio diversification: Growth in China is anticipated to remain robust, with management increasing its forecast to mid- to high-single digits for the year, driven by commercial investments and e-commerce expansion. However, executives cautioned that policy risk remains a potential headwind in the region.
- Cost discipline and capital allocation: The company plans to maintain a disciplined cost structure, targeting $120 million in net savings this year, and will continue balancing shareholder returns with business development investments. Management cited ongoing strategic review and cash generation as key enablers for future growth and M&A opportunities.
Catalysts in Upcoming Quarters
Looking forward, the StockStory team will be tracking (1) regulatory decisions and launches for XULANE LO and fast-acting meloxicam in the U.S., (2) sustained revenue growth and commercial execution in Greater China amid evolving policy dynamics, and (3) progress on cost optimization and pipeline milestones, including Phase III data for selatogrel and cenerimod. Updates on business development and M&A activity will also be closely watched.
Viatris currently trades at $17.28, up from $15.95 just before the earnings. Is there an opportunity in the stock?See for yourself in our full research report (it’s free).
Now Could Be The Perfect Time To Invest In These Stocks
ONE MORE THING: Top 6 Stocks for This Week. This market is separating quality stocks from expensive ones fast. AI taking down whole sectors with no warning. In a rotation this fast, you need more than a list of good companies.
Our AI system flagged Palantir before it ran 1,662%. AppLovin before it ran 753%. Nvidia before it ran 1,178%. Each week it produces 6 new names that pass the same tests. Get Our Top 6 Stocks for Free HERE.
Stocks that have made our list include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+354% five-year return). Find your next big winner with StockStory today.
